President and CEO Krishnan Krish S sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,533,056 units (SEC Form 4)
$KRYS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 03/13/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 03/13/2025 | S | 1,100(1) | D | $175.8256(2) | 1,556,956 | D | |||
| Common Stock | 03/13/2025 | S | 4,944(1) | D | $176.8048(3) | 1,552,012 | D | |||
| Common Stock | 03/13/2025 | S | 10,931(1) | D | $177.6243(4) | 1,541,081 | D | |||
| Common Stock | 03/13/2025 | S | 6,769(1) | D | $178.7674(5) | 1,534,312 | D | |||
| Common Stock | 03/13/2025 | S | 1,256(1) | D | $179.5735(6) | 1,533,056 | D | |||
| Common Stock | 90,000 | I | By Krishnan Spousal Trust | |||||||
| Common Stock | 50,000 | I | By Krishnan Family Trust(7) | |||||||
| Common Stock | 03/13/2025 | S | 1,639(8) | D | $175.9724(9) | 1,487,072 | I | By Spouse(10) | ||
| Common Stock | 03/13/2025 | S | 4,579(8) | D | $176.8779(11) | 1,482,493 | I | By Spouse(10) | ||
| Common Stock | 03/13/2025 | S | 10,937(8) | D | $177.6563(12) | 1,471,556 | I | By Spouse(10) | ||
| Common Stock | 03/13/2025 | S | 6,514(8) | D | $178.7558(13) | 1,465,042 | I | By Spouse(10) | ||
| Common Stock | 03/13/2025 | S | 1,331(8) | D | $179.5466(14) | 1,463,711 | I | By Spouse(10) | ||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Explanation of Responses: |
| 1. The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. |
| 2. The transaction was executed in multiple trades ranging from $175.23 to $176.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 3. The transaction was executed in multiple trades ranging from $176.28 to $177.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 4. The transaction was executed in multiple trades ranging from $177.28 to $178.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 5. The transaction was executed in multiple trades ranging from $178.29 to $179.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 6. The transaction was executed in multiple trades ranging from $179.29 to $179.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 7. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. |
| 8. The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. |
| 9. The transaction was executed in multiple trades ranging from $175.30 to $176.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 10. Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. |
| 11. The transaction was executed in multiple trades ranging from $176.30 to $177.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 12. The transaction was executed in multiple trades ranging from $177.30 to $178.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 13. The transaction was executed in multiple trades ranging from $178.31 to $179.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 14. The transaction was executed in multiple trades ranging from $179.33 to $179.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Remarks: |
| /s/ Krish S. Krishnan | 03/13/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||